stockrow
Friday 6 November 2026
Export ELAN’s income statement to Excel — free account
Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +11.3%
- EPS
- +157.1%
- Free cash flow
- +22.8%
- Total debt
- −6.91%
Quarter to September 2026, against a year earlier
25.68
2.00
+8.45%
Follow ELAN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.38 | 2.43 | 2.45 | 2.17 | |
P/FCF ratio |
42.88 | 40.65 | 34.43 | 28.99 | |
P/Operating CF |
104.01 | 916.15 | 44.38 | 51.80 | |
P/B ratio |
1.72 | 1.83 | 1.87 | 1.69 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.12 | 3.16 | 3.12 | 2.84 | |
EV/EBITDA |
21.16 | 20.71 | 20.26 | 18.92 | |
EV/Operating CF |
26.26 | 26.82 | 25.41 | 23.85 | |
EV/FCF |
56.13 | 52.81 | 43.92 | 37.93 | |
Quick Ratio |
0.93 | 0.95 | 0.91 | 0.86 | |
Current Ratio |
2.17 | 2.16 | 2.05 | 2.09 | |
Net Debt/EBITDA |
(385.78) | 10.96 | 12.10 | 0.00 | |
Debt/Assets |
30.07% | 30.18% | 28.89% | 0.00% | |
Debt/Equity |
0.61 | 0.61 | 0.59 | 0.00 | |
Asset Turnover |
0.36 | 0.37 | 0.37 | 0.38 | |
Operating CF/Net income |
(0.39) | 0.23 | 5.13 | 12.00 | |
Capex/Depreciation |
(0.36) | (0.30) | (0.19) | (0.34) | |
Interest Coverage |
(2.29) | 2.68 | 1.85 | 0.00 | |
Research and Development Expense of Revenue |
8.13% | 7.08% | 6.73% | 7.83% | |
Selling, General and Administrative Expense of Revenue |
29.55% | 27.79% | 32.82% | 31.07% | |
Intangible Assets out of Total Assets |
0.61 | 0.60 | 0.59 | 0.59 | |
Share Based Compensation of Revenue |
1.40% | 1.53% | 1.46% | 1.58% | |
Graham Net Nets |
(0.30) | (0.26) | (0.26) | (0.27) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.08%) | (2.09%) | (1.67%) | (1.34%) | |
Free Cash Flow Yield |
2.33% | 2.46% | 2.90% | 3.45% | |
Revenue per Share |
2.30 | 2.75 | 2.74 | 2.53 | |
Operating CF per Share |
0.22 | 0.03 | 0.55 | 0.43 | |
Capex per Share |
(0.12) | (0.10) | (0.07) | (0.12) | |
Free Cash Flow per Share |
0.09 | (0.08) | 0.49 | 0.31 | |
Cash per Share |
1.10 | 0.86 | 1.06 | 0.93 | |
Shareholders Equity per Share |
13.19 | 13.06 | 13.19 | 13.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.19 | 13.06 | 13.19 | 13.26 | |
Free Cash Flow |
46.00 | (38.00) | 244.00 | 156.00 | |
Working Capital |
1,861.00 | 1,922.00 | 1,945.00 | 1,939.00 | |
Capital Expenditures |
(62.00) | (51.00) | (33.00) | (60.00) | |
Net Current Asset Value |
(3,353.00) | (3,138.00) | (3,176.00) | (2,986.00) | |
EV/EBIT |
980.37 | 276.30 | 193.59 | 180.76 | |
Capex to Sales |
0.05 | 0.04 | 0.02 | 0.05 | |
Price to Operating Income |
748.90 | 212.68 | 151.76 | 138.13 | |
| Other line items | |||||
Average Receivables |
913.00 | 1,107.00 | 1,127.50 | 1,019.00 | |
Average Payables |
332.00 | 351.00 | 397.50 | 384.00 | |
Average Inventory |
1,655.50 | 1,654.50 | 1,719.50 | 1,763.00 | |
Average Assets |
12,986.00 | 13,081.50 | 13,651.50 | 13,445.50 | |
Average Common Equity |
6,321.50 | 6,426.50 | 6,681.50 | 6,688.50 |
Columns are period end dates · fundamentals updated 6 Nov 2026